It was an absolute pleasure to discuss the 24-week results from the SKIPPAIN study (NCT03136861) with Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany). The study, which is a phase IIIb trial, evaluated the efficacy and safety of secukinumab in reducing spinal pain and disease activity following a step-up dosing approach.
His presentation entitled ‘Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial’ (ABSTRACT NUMBER: 0899) was presented at ACR Convergence 2020, 5-9 November.
Disclosures: Denis Poddubnyy reports grants and personal fees from AbbVie, personal fees from Bristol-Myers Squibb, grants and personal fees from Eli Lilly, grants and personal fees from MSD, grants and personal fees from Novartis, grants and personal fees from Pfizer, personal fees from Roche, personal fees from UCB, personal fees from Biocad, personal fees from GlaxoSmithKline and personal fees from Gilead.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
